Genedx Holdings Corp Stock Analysis
| WGS Stock | 91.24 6.95 8.25% |
IPO Date 4th of November 2020 | 200 Day MA 109.7693 | 50 Day MA 128.6196 | Beta 2.022 |
At this time, GeneDx Holdings' Net Debt is comparatively stable compared to the past year. Short Term Debt is likely to gain to about 5.6 M in 2026, whereas Long Term Debt is likely to drop slightly above 31 M in 2026. GeneDx Holdings' financial risk is the risk to GeneDx Holdings stockholders that is caused by an increase in debt.
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.25 | Current Value 0.15 | Quarterly Volatility 0.05197843 |
GeneDx Holdings Corp is undervalued with Real Value of 110.2 and Target Price of 170.0. The main objective of GeneDx Holdings stock analysis is to determine its intrinsic value, which is an estimate of what GeneDx Holdings Corp is worth, separate from its market price. There are two main types of GeneDx Holdings' stock analysis: fundamental analysis and technical analysis.
The GeneDx Holdings stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. GeneDx Holdings is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. GeneDx Stock trading window is adjusted to America/New York timezone.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in GeneDx Holdings Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. GeneDx Stock Analysis Notes
About 12.0% of the company outstanding shares are owned by insiders. The company had not issued any dividends in recent years. GeneDx Holdings Corp had 1:33 split on the 4th of May 2023. For more information please call Katherine Stueland at 888 729 1206 or visit https://www.genedx.com.GeneDx Holdings Quarterly Total Revenue |
|
GeneDx Holdings Corp Investment Alerts
| GeneDx Holdings Corp generated a negative expected return over the last 90 days | |
| GeneDx Holdings Corp has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 305.45 M. Reported Net Loss for the year was (52.29 M) with profit before taxes, overhead, and interest of 280.11 M. | |
| GeneDx Holdings generates negative cash flow from operations | |
| GeneDx Holdings Corp has a frail financial position based on the latest SEC disclosures | |
| Over 88.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from prnewswire.com: CanSinoBIO at WGS 2026 Accelerating Global Access to Innovative Vaccines |
GeneDx Largest EPS Surprises
Earnings surprises can significantly impact GeneDx Holdings' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-15 | 2022-06-30 | -0.21 | -0.25 | -0.04 | 19 | ||
2025-10-28 | 2025-09-30 | 0.41 | 0.49 | 0.08 | 19 | ||
2023-03-14 | 2022-12-31 | -0.16 | -0.25 | -0.09 | 56 |
GeneDx Holdings Environmental, Social, and Governance (ESG) Scores
GeneDx Holdings' ESG score is a quantitative measure that evaluates GeneDx Holdings' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of GeneDx Holdings' operations that may have significant financial implications and affect GeneDx Holdings' stock price as well as guide investors towards more socially responsible investments.
GeneDx Market Capitalization
The company currently falls under 'Mid-Cap' category with a total capitalization of 2.64 B.GeneDx Profitablity
The company has Net Profit Margin of 0.01 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of (0.03) %, which entails that for every $100 of revenue, it lost $0.03.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.06) | (0.06) | |
| Return On Assets | (0.11) | (0.12) | |
| Return On Equity | (0.19) | (0.20) |
Management Efficiency
GeneDx Holdings Corp has Return on Asset of 0.0162 % which means that on every $100 spent on assets, it made $0.0162 of profit. This is way below average. GeneDx Holdings' management efficiency ratios could be used to measure how well GeneDx Holdings manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.19 in 2026. Return On Capital Employed is likely to drop to -0.06 in 2026. At this time, GeneDx Holdings' Net Tangible Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 12.8 M in 2026, whereas Total Assets are likely to drop slightly above 481.6 M in 2026.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.49 | 9.96 | |
| Tangible Book Value Per Share | 3.71 | 3.52 | |
| Enterprise Value Over EBITDA | -1.9 K | -1.8 K | |
| Price Book Value Ratio | 9.69 | 9.21 | |
| Enterprise Value Multiple | -1.9 K | -1.8 K | |
| Price Fair Value | 9.69 | 9.21 | |
| Enterprise Value | 1.9 B | 2 B |
At GeneDx Holdings Corp, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Technical Drivers
As of the 10th of February, GeneDx Holdings retains the Risk Adjusted Performance of (0.11), market risk adjusted performance of (0.33), and Standard Deviation of 3.93. Concerning fundamental indicators, the technical analysis model lets you check existing technical drivers of GeneDx Holdings Corp, as well as the relationship between them. Please check out GeneDx Holdings Corp market risk adjusted performance and treynor ratio to decide if GeneDx Holdings is priced fairly, providing market reflects its last-minute price of 91.24 per share. Given that GeneDx Holdings Corp has information ratio of (0.17), we strongly advise you to confirm GeneDx Holdings Corp's regular market performance to make sure the company can sustain itself at a future point.GeneDx Holdings Corp Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in GeneDx Holdings price series with the more recent values given greater weights.
GeneDx Holdings Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GeneDx Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on GeneDx Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GeneDx Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
GeneDx Holdings Outstanding Bonds
GeneDx Holdings issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GeneDx Holdings Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GeneDx bonds can be classified according to their maturity, which is the date when GeneDx Holdings Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
GeneDx Holdings Predictive Daily Indicators
GeneDx Holdings intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GeneDx Holdings stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 39486.84 | |||
| Daily Balance Of Power | 1.430041 | |||
| Rate Of Daily Change | 1.08 | |||
| Day Median Price | 89.31 | |||
| Day Typical Price | 89.95 | |||
| Price Action Indicator | 5.4 | |||
| Period Momentum Indicator | 6.95 |
GeneDx Holdings Corporate Filings
F4 | 6th of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 3rd of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 2nd of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 12th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 18th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 11th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 3rd of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 26th of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
GeneDx Holdings Forecast Models
GeneDx Holdings' time-series forecasting models are one of many GeneDx Holdings' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GeneDx Holdings' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.GeneDx Holdings Bond Ratings
GeneDx Holdings Corp financial ratings play a critical role in determining how much GeneDx Holdings have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for GeneDx Holdings' borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | (2.73) | Unlikely Manipulator | View |
GeneDx Holdings Other Current Liab Over Time
GeneDx Holdings Assets Financed by Debt
The debt-to-assets ratio shows the degree to which GeneDx Holdings uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.GeneDx Holdings Debt Ratio | 15.0 |
GeneDx Holdings Corporate Bonds Issued
GeneDx Short Long Term Debt Total
Short Long Term Debt Total |
|
About GeneDx Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how GeneDx Holdings prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling GeneDx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as GeneDx Holdings. By using and applying GeneDx Stock analysis, traders can create a robust methodology for identifying GeneDx entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.20) | (0.21) | |
| Operating Profit Margin | (0.07) | (0.07) | |
| Net Loss | (0.15) | (0.16) | |
| Gross Profit Margin | 0.57 | 0.60 |
Current GeneDx Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. GeneDx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. GeneDx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 170.0 | Strong Buy | 6 | Odds |
Most GeneDx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand GeneDx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of GeneDx Holdings Corp, talking to its executives and customers, or listening to GeneDx conference calls.
GeneDx Stock Analysis Indicators
GeneDx Holdings Corp stock analysis indicators help investors evaluate how GeneDx Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading GeneDx Holdings shares will generate the highest return on investment. By understating and applying GeneDx Holdings stock analysis, traders can identify GeneDx Holdings position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 100.7 M | |
| Long Term Debt | 51.9 M | |
| Common Stock Shares Outstanding | 26.9 M | |
| Total Stockholder Equity | 245.2 M | |
| Total Cashflows From Investing Activities | -30.1 M | |
| Tax Provision | -343 K | |
| Property Plant And Equipment Net | 58.5 M | |
| Cash And Short Term Investments | 141.2 M | |
| Cash | 85.2 M | |
| Accounts Payable | 8 M | |
| Net Debt | 31 M | |
| 50 Day M A | 128.6196 | |
| Total Current Liabilities | 54.8 M | |
| Other Operating Expenses | 328.7 M | |
| Non Current Assets Total | 221.4 M | |
| Forward Price Earnings | 72.4638 | |
| Non Currrent Assets Other | 4.3 M | |
| Stock Based Compensation | 9.1 M |
Additional Tools for GeneDx Stock Analysis
When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.